search
Back to results

Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Primary Purpose

Medium-chain Acyl-CoA Dehydrogenase Deficiency

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Triheptanoin
Sponsored by
Jerry Vockley, MD, PhD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Medium-chain Acyl-CoA Dehydrogenase Deficiency focused on measuring Medium-chain Acyl-CoA Dehydrogenase Deficiency

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: A diagnosis of MCAD deficiency with molecular confirmation. Age criteria age ≥ 16 years Able to perform and comply with study activities including overnight admission to the research unit at UPMC Children's Hospital Pittsburgh, placement of an IV catheter, and all blood draws. Negative pregnancy test for all female subjects of child bearing age. Females of childbearning potential must agree to use a highly effective method of contraception, and males must agree not to father a child or donate sperm. True abstinence for the duration of the study will also be accepted. Signed informed consent for subjects ≥ 18 years, or assent by subjects age 16-17 years with parental consent for underaged subjects. Exclusion Criteria: Use of any investigational drug within 30 days of screening. Active infection (viral or bacterial) or any other intercurrent condition as reported by the subject or noted on physical exam at screening. Evidence of liver disease as defined by elevations of AST or ALT> 1.5x ULN at screening Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk by participating in this study. Pregnant, planning to become pregnant, breastfeeding or lactating females. Diagnosis of pancreatic insufficiency or concomitant use of a pancreatic lipase inhibitor (e.g. Orlistat) which can interfere with absorption of triheptanoin Subjects with type 1 or type 2 diabetes, or who take medications as part of their routine care that can cause hypoglycemia

Sites / Locations

  • UPMC Children's Hospital of PittsburghRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Triheptanoin

Arm Description

Open label study

Outcomes

Primary Outcome Measures

Number of participants with treatment related adverse events as assessed by CTCAE v5.0

Secondary Outcome Measures

Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C2 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C3 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C6 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C8 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C10 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C10:1 ratio levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C16 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine n-propionylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine suberylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine n-octanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine n-hexanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C2 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C3 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C6 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C8 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C10 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C10:1 ratio levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (plasma acylcarnitine)
Change in C16 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine n-propionylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine suberylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine n-octanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Normalization of biochemical markers of disease (urine acylglycine)
Change in urine n-hexanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine

Full Information

First Posted
August 10, 2023
Last Updated
September 27, 2023
Sponsor
Jerry Vockley, MD, PhD
Collaborators
Ultragenyx Pharmaceutical Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT06067802
Brief Title
Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Official Title
A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 30, 2023 (Anticipated)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
February 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jerry Vockley, MD, PhD
Collaborators
Ultragenyx Pharmaceutical Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with MCADD.
Detailed Description
Participation in the study will require three overnight admissions at the Clinical and Translational Research Center at the UPMC Children's Hospital of Pittsburgh (also called the PCTRC). The total length of the study is 10 weeks. Subjects will have blood work and an intravenous access line (IV) placed for several blood draws during the visit. Subjects will begin fasting during the admission, which means they may consume only non-caloric fluids (water, unsweetened black coffee or tea, or sugar-free beverages). Bloodwork will be collected during the fast. Following the completion of the fast, the subject will eat a meal and will receive the study drug, triheptanoin. The total time of fasting will be up to 24 hours. Dosing for this study will begin at 0.2 gm/kg/day up to a dose of 1.0 gm/kg/day. The dose will be increased gradually to avoid gastric upset. The dose should be divided into 3 or 4 daily doses and given with food or liquid. The dose can be decreased if a subject experiences any gastric upset that indicates that they cannot tolerate the higher dose. Subjects will return two more times (at Weeks 5 and 9) to undergo the overnight admission and 24-hour fasting procedures outlined above. After the Week 9 admission they will no longer take the triheptanoin. Study staff will contact them by phone one week later (Week 10) to make sure they are not experiencing any adverse effects. All study procedures will be done at no cost to the subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Keywords
Medium-chain Acyl-CoA Dehydrogenase Deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Triheptanoin
Arm Type
Experimental
Arm Description
Open label study
Intervention Type
Drug
Intervention Name(s)
Triheptanoin
Other Intervention Name(s)
Dojolvi
Intervention Description
Open-label design with doses of triheptanoin up to 1.0 gm/kg triheptanoin
Primary Outcome Measure Information:
Title
Number of participants with treatment related adverse events as assessed by CTCAE v5.0
Time Frame
10 weeks
Secondary Outcome Measure Information:
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C2 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C3 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C6 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C8 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C10 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C10:1 ratio levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C16 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine n-propionylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine suberylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine n-octanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine n-hexanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C2 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C3 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C6 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C8 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C10 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C10:1 ratio levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (plasma acylcarnitine)
Description
Change in C16 levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in nmol/mL
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine n-propionylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine suberylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine n-octanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Time Frame
10 weeks
Title
Normalization of biochemical markers of disease (urine acylglycine)
Description
Change in urine n-hexanoylglycine levels, comparing results from the fast before and after triheptanoin is initiated - this will be measured by the actual change from baseline to Week 10 for each participant; measured in mg/g creatinine
Time Frame
10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of MCAD deficiency with molecular confirmation. Age criteria age ≥ 16 years Able to perform and comply with study activities including overnight admission to the research unit at UPMC Children's Hospital Pittsburgh, placement of an IV catheter, and all blood draws. Negative pregnancy test for all female subjects of child bearing age. Females of childbearning potential must agree to use a highly effective method of contraception, and males must agree not to father a child or donate sperm. True abstinence for the duration of the study will also be accepted. Signed informed consent for subjects ≥ 18 years, or assent by subjects age 16-17 years with parental consent for underaged subjects. Exclusion Criteria: Use of any investigational drug within 30 days of screening. Active infection (viral or bacterial) or any other intercurrent condition as reported by the subject or noted on physical exam at screening. Evidence of liver disease as defined by elevations of AST or ALT> 1.5x ULN at screening Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk by participating in this study. Pregnant, planning to become pregnant, breastfeeding or lactating females. Diagnosis of pancreatic insufficiency or concomitant use of a pancreatic lipase inhibitor (e.g. Orlistat) which can interfere with absorption of triheptanoin Subjects with type 1 or type 2 diabetes, or who take medications as part of their routine care that can cause hypoglycemia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth McCracken, MS, CGC
Phone
412-692-5662
Email
elizabeth.mccracken@chp.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerard Vockley, MD, PhD
Organizational Affiliation
UPMC Children's Hospital of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
UPMC Children's Hospital of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth McCracken, MS, CGC
Phone
412-692-5662
Email
elizabeth.mccracken@chp.edu
First Name & Middle Initial & Last Name & Degree
Gerard Vockley, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

We'll reach out to this number within 24 hrs